Obesity doesn't play by the same rules at every age — especially for women. A new narrative review published in Obesity Pillars examined how obesity-related risks, complications, and treatment options shift across four key life stages: puberty, reproductive age, perimenopause, and postmenopause. The findings paint a clear picture: one-size-fits-all obesity care isn't cutting it.

From early puberty through older age, the consequences compound. In adolescence, obesity is tied to earlier puberty and conditions like type 2 diabetes and polycystic ovary syndrome (now called PMOS). During reproductive years, it raises the risk of infertility, miscarriage, preeclampsia, and birth defects. Around menopause, cardiometabolic risks and mental health symptoms spike. And in postmenopause, obesity is linked to several cancers, osteoarthritis, and loss of bladder control.

GLP-1 receptor agonists and other newer weight-loss medications showed effectiveness across all life stages — but none are approved during pregnancy or breastfeeding, and long-term effects on bone health, cancer risk, and physical function remain understudied.

Key Takeaways:

• Obesity medications (including some GLP-1s) are now approved for adolescents, but must be discontinued before conception
• Semaglutide reduced major cardiovascular events in later life; tirzepatide improved sleep apnea outcomes
• Data on obesity medications' effects on PMOS symptoms and menstrual regularity were mixed
• Large clinical trials focused on women's life-stage-specific outcomes are urgently needed

Why it matters: With obesity rates in U.S. women projected to hit nearly 59% by 2050, closing these research gaps and tailoring treatment to each life stage isn't just good medicine — it's a public health imperative.